3XB0 Stock Overview

A biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. More details

3XB0 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 35.9% per year

Earnings have grown 31.3% per year over the past 5 years

Risk Analysis

Does not have a meaningful market cap (€6M)

Earnings are forecast to decline by an average of 34.4% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have meaningful revenue ($3M)

My Notes

Capture your thoughts, links and company narrative

Xenetic Biosciences, Inc. Competitors

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€15.2m

Sangui Biotech International

HMSE:SBH

€419.8k

Heidelberg Pharma

XTRA:HPHA

€101.6m

Price History & Performance

Summary of share price highs, lows and changes for Xenetic Biosciences
Historical stock prices
Current Share Price	US$3.86
52 Week High	US$4.28
52 Week Low	US$2.98
Beta	2.24
1 Month Change	0%
3 Month Change	10.92%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	7.82%

Recent updates

Shareholder Returns

	3XB0	DE Biotechs	DE Market
7D	0%	1.2%	-0.3%
1Y	n/a	-14.3%	7.0%

Return vs Industry: Insufficient data to determine how 3XB0 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 3XB0 performed against the German Market.

Price Volatility

Is 3XB0's price volatile compared to industry and market?
3XB0 volatility
3XB0 Average Weekly Movement	n/a
Biotechs Industry Average Movement	7.0%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.6%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: Data is not available.

Volatility Over Time: Insufficient data to determine 3XB0's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	4	Jim Parslow	www.xeneticbio.com

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company’s proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors.

Xenetic Biosciences, Inc. Fundamentals Summary

How do Xenetic Biosciences's earnings and revenue compare to its market cap?
3XB0 fundamental statistics
Market cap	€6.15m
Earnings (TTM)	-€3.92m
Revenue (TTM)	€2.43m

2.5x

P/S Ratio

-1.6x

P/E Ratio

Is 3XB0 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
3XB0 income statement (TTM)
Revenue	US$2.52m
Cost of Revenue	US$0
Gross Profit	US$2.52m
Other Expenses	US$6.60m
Earnings	-US$4.08m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-2.64
Gross Margin	100.00%
Net Profit Margin	-161.58%
Debt/Equity Ratio	0%

How did 3XB0 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/25 04:35
End of Day Share Price	2024/10/31 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Xenetic Biosciences, Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Joseph Pantginis	H.C. Wainwright & Co.
Kevin DeGeeter	Ladenburg Thalmann & Company
Rahul Jasuja	NOBLE Capital Markets, Inc.